论文部分内容阅读
本文用生物素—链霉亲和素酶联免疫吸附试验（BSA）对203例血清CA19－9水平进行定量测定。结果显示，在32例胰腺癌组为826±411U／ml，40例肝癌组为107±46．5U／ml，与76例正常人对照组21．2±9．24U／ml比较均有明显差异（P＜0．05），以胰腺癌组升高最显著。在39例胃癌组为25．4±11．0U／ml，与正常对照组比较均无明显差异（P＞0．05）。27例胰腺癌病人术前为910±452U／ml，术后为187±89．0U／ml，血清CA19－9水平明显下降（P＜0．05）。血清CA19－9水平分析对胰腺癌的鉴别诊断、疗效观察及预后评估有较高价值。
In this study, 203 serum CA19-9 levels were quantitatively determined by biotin-streptavidin enzyme-linked immunosorbent assay (BSA). The results showed that 32 cases of pancreatic cancer group were 826±411 U/ml, and 40 cases of liver cancer group were 107±46.5 U/ml, which were significantly different from the 76 normal control group of 21.2±9.24 U/ml. (P < 0.05), the most significant increase in the pancreatic cancer group. In the 39 cases of gastric cancer was 25.4 ± 11.0U/ml, there was no significant difference compared with the normal control group (P> 0.05). Twenty-seven patients with pancreatic cancer were preoperatively 910±452 U/ml, postoperatively 187±89.0 U/ml, serum CA19-9 levels were significantly decreased (P<0.05). The analysis of serum CA19-9 levels has high value for the differential diagnosis, curative effect observation and prognosis evaluation of pancreatic cancer.